FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806467428> ?p ?o ?g. }

• W2806467428 abstract "Traditionally, radical prostatectomy and radiotherapy with or without androgen deprivation therapy have been the main treatment options to attempt to cure men with localised or locally advanced prostate cancer. Cryotherapy is an alternative option for treatment of prostate cancer that involves freezing of the whole prostate (whole gland therapy) or only the cancer (focal therapy), but it is unclear how effective this is in comparison to other treatments.To assess the effects of cryotherapy (whole gland or focal) compared with other interventions for primary treatment of clinically localised (cT1-T2) or locally-advanced (cT3) non-metastatic prostate cancer.We updated a previously published Cochrane Review by performing a comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE), clinical trial registries (ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform) and a grey literature repository (Grey Literature Report) up to 6 March 2018. We also searched the reference lists of other relevant publications and conference proceedings. We applied no language restrictions.We included randomised or quasi-randomised trials comparing cryotherapy to other interventions for the primary treatment of prostate cancer.Two independent reviewers screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the quality of evidence (QoE) according to the GRADE approach.We included only one comparison of whole gland cryotherapy versus external beam radiotherapy, which was informed by two trials with a total of 307 randomised participants. The median age of the included studies was around 70 years. The median follow-up of included studies ranged from 100 to 105 months.Primary outcomes: we are uncertain about the effect of whole gland cryotherapy compared to radiation therapy on time to death from prostate cancer; hazard ratio (HR) of 1.00 (95% confidence interval (CI) 0.11 to 9.45; 2 trials, 293 participants; very low QoE); this would correspond to zero fewer death from prostate cancer per 1000 men (95% CI 85 fewer to 520 more). We are equally uncertain about the effect of quality of life-related urinary function and bowel function (QoL) at 36 months using the UCLA-Prostate Cancer Index score for which higher values (range: 0 to 100) reflect better quality of life using minimal clinically important differences (MCID) of 8 and 7 points, respectively; mean difference (MD) of 4.4 (95% CI -6.5 to 15.3) and 4.0 (95% CI -73.96 to 81.96), respectively (1 trial, 195 participants; very low QoE). We are also uncertain about sexual function-related QoL using a MCID of 8 points; MD of -20.7 (95% CI -36.29 to -5.11; 1 trial, 195 participants; very low QoE). Lastly, we are uncertain of the risk for major adverse events; risk ratio (RR): 0.91 (95% CI 0.47 to 1.78; 2 trials, 293 participants; very low QoE); this corresponds to 10 fewer major adverse events per 1000 men (95% CI 58 fewer to 86 more).we are very uncertain about the effects of cryotherapy on time to death from any cause (HR 0.99, 95% CI 0.05 to 18.79; 2 trials, 293 participants; very low QoE), and time to biochemical failure (HR 2.15, 95% CI 0.07 to 62.12; 2 trials, 293 participants; very low QoE). Rates of secondary interventions for treatment failure and minor adverse events were either not reported in the trials, or the data could not be used for analyses.We found no trials that compared whole gland cryotherapy or focal cryotherapy to other treatment forms such as radical surgery, active surveillance, watchful waiting or other forms of radiotherapy.Based on very low quality evidence, primary whole gland cryotherapy has uncertain effects on oncologic outcomes, QoL, and major adverse events compared to external beam radiotherapy. Reasons for downgrading the QoE included serious study limitations, indirectness due to the use of lower doses of radiation in the comparison group than currently recommended, and serious or very serious imprecision." @default.
• W2806467428 created "2018-06-13" @default.
• W2806467428 creator A5001861927 @default.
• W2806467428 creator A5004803392 @default.
• W2806467428 creator A5014757964 @default.
• W2806467428 creator A5018944921 @default.
• W2806467428 creator A5022732774 @default.
• W2806467428 creator A5042288631 @default.
• W2806467428 date "2018-05-30" @default.
• W2806467428 modified "2023-10-16" @default.
• W2806467428 title "Primary cryotherapy for localised or locally advanced prostate cancer" @default.
• W2806467428 cites W1594514919 @default.
• W2806467428 cites W1962829821 @default.
• W2806467428 cites W1965134014 @default.
• W2806467428 cites W1974182592 @default.
• W2806467428 cites W1974635901 @default.
• W2806467428 cites W1976576973 @default.
• W2806467428 cites W1980789427 @default.
• W2806467428 cites W1986114421 @default.
• W2806467428 cites W1986248057 @default.
• W2806467428 cites W1991359895 @default.
• W2806467428 cites W2004718514 @default.
• W2806467428 cites W2018779708 @default.
• W2806467428 cites W2019095051 @default.
• W2806467428 cites W2023851593 @default.
• W2806467428 cites W2041940347 @default.
• W2806467428 cites W2054214622 @default.
• W2806467428 cites W2054307343 @default.
• W2806467428 cites W2054884203 @default.
• W2806467428 cites W2057434007 @default.
• W2806467428 cites W2061394445 @default.
• W2806467428 cites W2062817759 @default.
• W2806467428 cites W2069245461 @default.
• W2806467428 cites W2070638378 @default.
• W2806467428 cites W2071693341 @default.
• W2806467428 cites W2075120811 @default.
• W2806467428 cites W2075642745 @default.
• W2806467428 cites W2085194595 @default.
• W2806467428 cites W2090132603 @default.
• W2806467428 cites W2093867637 @default.
• W2806467428 cites W2104675861 @default.
• W2806467428 cites W2105386786 @default.
• W2806467428 cites W2106787323 @default.
• W2806467428 cites W2108556695 @default.
• W2806467428 cites W2109188829 @default.
• W2806467428 cites W2120767646 @default.
• W2806467428 cites W2123957818 @default.
• W2806467428 cites W2125435699 @default.
• W2806467428 cites W2126930838 @default.
• W2806467428 cites W2129381662 @default.
• W2806467428 cites W2134236426 @default.
• W2806467428 cites W2135410692 @default.
• W2806467428 cites W2140203312 @default.
• W2806467428 cites W2148092778 @default.
• W2806467428 cites W2156549595 @default.
• W2806467428 cites W2160537008 @default.
• W2806467428 cites W2167571044 @default.
• W2806467428 cites W2168187135 @default.
• W2806467428 cites W241447704 @default.
• W2806467428 cites W2418761016 @default.
• W2806467428 cites W2497093041 @default.
• W2806467428 cites W2523396458 @default.
• W2806467428 cites W2560077513 @default.
• W2806467428 cites W2588681363 @default.
• W2806467428 cites W2766638908 @default.
• W2806467428 cites W2794712096 @default.
• W2806467428 cites W2916841405 @default.
• W2806467428 cites W3022903699 @default.
• W2806467428 cites W4301961722 @default.
• W2806467428 cites W4317528128 @default.
• W2806467428 cites W822517327 @default.
• W2806467428 cites W33251043 @default.
• W2806467428 doi "https://doi.org/10.1002/14651858.cd005010.pub3" @default.
• W2806467428 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6494517" @default.
• W2806467428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29845595" @default.
• W2806467428 hasPublicationYear "2018" @default.
• W2806467428 type Work @default.
• W2806467428 sameAs 2806467428 @default.
• W2806467428 citedByCount "10" @default.
• W2806467428 countsByYear W28064674282018 @default.
• W2806467428 countsByYear W28064674282020 @default.
• W2806467428 countsByYear W28064674282021 @default.
• W2806467428 countsByYear W28064674282022 @default.
• W2806467428 countsByYear W28064674282023 @default.
• W2806467428 crossrefType "journal-article" @default.
• W2806467428 hasAuthorship W2806467428A5001861927 @default.
• W2806467428 hasAuthorship W2806467428A5004803392 @default.
• W2806467428 hasAuthorship W2806467428A5014757964 @default.
• W2806467428 hasAuthorship W2806467428A5018944921 @default.
• W2806467428 hasAuthorship W2806467428A5022732774 @default.
• W2806467428 hasAuthorship W2806467428A5042288631 @default.
• W2806467428 hasBestOaLocation W28064674282 @default.
• W2806467428 hasConcept C118552586 @default.
• W2806467428 hasConcept C121608353 @default.
• W2806467428 hasConcept C126322002 @default.
• W2806467428 hasConcept C141071460 @default.
• W2806467428 hasConcept C142724271 @default.
• W2806467428 hasConcept C143998085 @default.
• W2806467428 hasConcept C168563851 @default.
• W2806467428 hasConcept C17744445 @default.

• next